[Treatment recommendations for various stages in diabetic nephropathy].
Takane
Hiroshi
H
Department of Nephrology, Saitama Medical School.
Suzuki
Hiromichi
H
D000419:Albuminuria / Q000652:urine; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000652:urine; D003404:Creatinine / Q000652:urine; D003928:Diabetic Nephropathies / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D004035:Diet Therapy; D018753:Diet, Protein-Restricted; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008657:Metabolic Clearance Rate; D006435:Renal Dialysis; D012720:Severity of Illness Index
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D004232:Diuretics; D007004:Hypoglycemic Agents; D003404:Creatinine